Earnings results for Crispr Therapeutics AG (NASDAQ:CRSP)
CRISPR Therapeutics AG is estimated to report earnings on 05/04/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts’ forecasts, the consensus EPS forecast for the quarter is $-1.09. The reported EPS for the same quarter last year was $-0.93.
Crispr Therapeutics last announced its quarterly earnings data on February 12th, 2020. The reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $1.19. The firm earned $77 million during the quarter, compared to analysts’ expectations of $39.08 million. Its quarterly revenue was up 76900.0% compared to the same quarter last year. Crispr Therapeutics has generated $1.17 earnings per share over the last year and currently has a price-to-earnings ratio of 55.7. Crispr Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, May 4th, 2020 based off prior year’s report dates.
Analyst Opinion on Crispr Therapeutics AG (NASDAQ:CRSP)
15 Wall Street analysts have issued ratings and price targets for Crispr Therapeutics in the last 12 months. Their average twelve-month price target is $74.42, suggesting that the stock has a possible upside of 37.79%. The high price target for CRSP is $104.00 and the low price target for CRSP is $31.00. There are currently 1 sell rating, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Crispr Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.73, and is based on 12 buy ratings, 2 hold ratings, and 1 sell rating. According to analysts’ consensus price target of $74.42, Crispr Therapeutics has a potential upside of 37.8% from its current price of $54.01. Crispr Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: Crispr Therapeutics AG (NASDAQ:CRSP)
Crispr Therapeutics does not currently pay a dividend. Crispr Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Crispr Therapeutics AG (NASDAQ:CRSP)
In the past three months, Crispr Therapeutics insiders have not sold or bought any company stock. Only 21.40% of the stock of Crispr Therapeutics is held by insiders. 51.99% of the stock of Crispr Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Crispr Therapeutics AG (NASDAQ:CRSP
Earnings for Crispr Therapeutics are expected to grow by 11.23% in the coming year, from ($4.54) to ($5.05) per share. The P/E ratio of Crispr Therapeutics is 55.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.86. The P/E ratio of Crispr Therapeutics is 55.68, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.70. Crispr Therapeutics has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here